John predicts Coursera will run two studies (biomarker and outcomes-based) for their PCSK9/angiotensinogen siRNA program
“we we expect to run, two studies for approval, one biomarker based and the other outcomes based? And so there will be an outcome study. There'll need to be. I I don't think the outcomes data will, be an impediment for for Lufendra's, initial launch.”
→ Read the source episode
Our resolution criterion
disputableCoursera initiates and completes biomarker-based and outcomes-based clinical studies for their siRNA program
More from Biotech Hangout
Tarsus Pharmaceuticals' Alkias phase three Northstar study for gilderretinol will report data in H2 2029.
Ten X will meet with EMA to explore enriched patient populations for HFpEF drug following failed phase three.
Brian Skorney predicts Lilly's Lp(a) CVOT data may read out in 2029.
Daphne Zohar predicts Heidi Overton's FDA commissioner confirmation hearings will occur after the Senate summer recess.
Eric Schmidt predicts the HARMONY three study for evanesquimab will read out positively in 6-9 months.
Paul Matisse reports Biohaven's KV7 epilepsy drug is on partial clinical hold with phase 3 data coming soon.
Summaries are ours; the quote is a verbatim transcript excerpt. Our resolution criteria are editorial and disputable. How this works.